✦ LIBER ✦

Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice

✍ Scribed by Frazier-Mironer, Aline; Dougados, Maxime; Mariette, Xavier; Cantagrel, Alain; Deschamps, Véronique; Flipo, René Marc; Logeart, Isabelle; Schaeverbeke, Thierry; Sibilia, Jean; Le Loët, Xavier; Combe, Bernard

Book ID: 122192262
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 858 KB
Volume: 81
Category: Article
ISSN: 1297-319X
DOI: 10.1016/j.jbspin.2014.02.014

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparative effectiveness and survival o

Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival

✍ Flouri, Irini; Markatseli, Theodora E.; Voulgari, Paraskevi V.; Boki, Kyriaki A. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 696 KB

Etanercept and adalimumab treatment in p

Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons leading to discontinuation of the treatment

✍ Tiina Levälampi; Markku Korpela; Katriina Vuolteenaho; Eeva Moilanen 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 341 KB

Direct comparison of treatment responses

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

✍ Merete Lund Hetland; Ib Jarle Christensen; Ulrik Tarp; Lene Dreyer; Annette Hans 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

Low infliximab serum trough levels and a

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study

✍ Aatke van der Maas, Bart JF van den Bemt, Gertjan Wolbink, Frank HJ van den Hoog 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 162 KB

Long-term anti-TNF therapy and the risk

Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry

✍ Atzeni, Fabiola; Sarzi-Puttini, Piercarlo; Botsios, Costantino; Carletto, Antoni 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 180 KB

C-reactive protein as a predictor of inf

C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: Defining subtypes of nonresponse and subsequent response to etanercept

✍ Maya H. Buch; Yohei Seto; Sarah J. Bingham; Victoria Bejarano; Domini Bryer; Jo 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 2 views